Expertise in
15
conditions

Yuqin W. Song

Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
Expertise in
15
conditions
Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 

Overview

Yuqin Song practices practicing medicine in Beijing, China.

Song is highly rated in 15 conditions, according to our data. Their clinical expertise encompasses Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Mastectomy.

They are actively involved in clinical research, co-authoring 344 peer reviewed articles and participating in 9 clinical trials.

Locations

Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China
Other Locations
No. 52 Fucheng Road, Haidian, 100142, China
52 Fucheng Road, Beijing, 100142, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: LOXO-305
Study Phase: Phase 2
A Phase 1 Study of CD19 and CD20 Targeted Chimeric Antigen Receptor T Cells Therapy (C-CAR039) in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
A Phase 1 Study of CD19 and CD20 Targeted Chimeric Antigen Receptor T Cells Therapy (C-CAR039) in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: January 30, 2026
Intervention Type: Biological
Study Drug: CD19/CD20-directed Chimeric Antigen Receptor T Cells
Study Phase: Phase 1
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: ATG-010
Study Phase: Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma
A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: April 03, 2024
Intervention Type: Biological
Study Drug: AK105
Study Phase: Phase 1/Phase 2
A Phase Ib Study of BTK Inhibitor DTRMWXHS-12 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
A Phase Ib Study of BTK Inhibitor DTRMWXHS-12 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drug: DTRMWXHS-12
Study Phase: Phase 1
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Relapsed or Refractory Peripheral T Cell Lymphoma
A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Relapsed or Refractory Peripheral T Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 19, 2022
Intervention Type: Biological
Study Drug: AK104
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

344 Total Publications

Research on a dynamic evolution model of driving fatigue-induced musculoskeletal disorders risk
Research on a dynamic evolution model of driving fatigue-induced musculoskeletal disorders risk
Journal: Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
Published: September 07, 2026

Frequently Asked Questions about Yuqin W. Song

Is Yuqin W. Song a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Yuqin W. Song is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yuqin W. Song participate in research or clinical trials?

Yes. Yuqin W. Song has published 344 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Yuqin W. Song's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Song's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile